About US

HURA has developed a novel CT technology which decreases radiation dose by
75% or greater without compromising image quality or clinical workflow.

OUR PURPOSE

HURA patented Hura CTP® technology will optimize patient safety and decrease radiation exposure for over 100 million CT Scans in the U.S. each year. Decreasing radiation exposure, particularly using dynamic perfusion imaging, is critically important for 1.2M heart attack and ~800K stroke scans each year.

OUR MISSION

Our mission is to introduce a new CT method that will decrease radiation emissions, optimizing the functional capabilities of CT scanners. Decreasing radiation exposure will also drive significant increases in overall CT scanning, particularly in Cardiac, GI, Mobile, Pediatric, and Whole-Body imaging applications.

Hura CTP® TECHNOLOGY
The Standard Method, which degrades images (causing ‘streaking artifacts’) compromise diagnostic validity, which is a barrier to clinical use.

Hura CTP® does not degrade image quality at 75% dose reduction.

EXAMPLE
Marked improvement in Hura CTP® : Reconstructed brain images produced from CT scans with 25% of the standard dose.

Hura CTP® TECHNOLOGY

Innovative, patent-pending image reconstruction methods which preserve image quality and speed without compromising workflow.

75%+ REDUCTION

Hura CTP® technology enables 75% or greater CT radiation dose reduction with no change to image quality or clinical workflow.

IMAGE QUALITY

The Standard Method degrades images (high noise) compromise diagnostic validity. Hura CTP® does not degrade image quality at 75% dose reduction.

OEM METHODS

Hura CTP® is complimentary to existing OEM dose reduction techniques: It can be used in addition to existing OEM Methods to further decrease radiation exposure.

Hura CTP®

Decreases radiation exposure and likelihood of
radiation-related cancer & conditions.

Our BENEFITS

Hura technology will significantly decrease CT radiation doses. Disrupting the $8B+ CT scanner market and significantly reduce cancer treatment costs: 2% of cancer treatment is estimated at ~$3B/year.
Patients

Patients

Decrease radiation exposure by 75% or greater and likelihood of radiation-related cancer & conditions.

 

Clinicians

Clinicians

Allow for more high dose CT exams (e.g. CT perfusion and angiography) for better diagnosis

Payers

Payers

Mitigation of radiation exposure disease costs. Improved healthcare service provision and quality.

FDA & Strategic Acquires

FDA & Strategic Acquires

Increased regulatory compliance. Improve function and competitiveness of CT scanners to drive sales.

NATIONAL INSTITUTE OF HEALTH

Funded by NIH STTR/SBIR Program

  • Awarded the NIH Small Business Technology Transfer (STTR) Phase 1 grant in 2017.
  • Awarded the NIH SBIR Phase 2 grant in 2020.
  • Brian Walsh, MS, MBA, Chief Commercial Advisor & National Institute of Health Advisor
  • Partnerships planned with a broad range of Cancer Philanthropic Organizations, as well as Oncology Research and Diagnostic Imaging Groups.

HURA ATTRIBUTES

EXCLUSIVE IP

EXCLUSIVE IP

HURA maintains exclusive IP and freedom to operate and license Hura CTP® Technology.

PATHWAY

PATHWAY

Phantom Validation Complete: Successful validation in American College of Radiology (ACR) phantom experiments, compliant with US FDA standards.

SUPPORT

SUPPORT

HURA has secured Letters of Support from OEMs supporting the development of Hura CTP® Technology.

FDA APPROVAL

FDA APPROVAL

FDA 510k application pending. Estimated 3-6 month FDA Clearance.

VETTED

VETTED

Hura CTP® Technology is funded by the prestigious U.S. National Institutes of Health Small Business Innovative Technology Research (SBIR) Commercialization Program.

PATIENTS

PATIENTS

Decrease radiation exposure and likelihood of radiation-related cancer & conditions.

Our Timeline

Our Fantastic Team

Hura is operated by World Leaders in the Medical Imaging Sector and
maintains exclusive dose reduction Intellectual Property (IP).

Marc Korczykowski, MB, MA

Co-Founder & Chief Executive Officer

Mr. Korczykowski served as a Senior Advisor at Brookline Capital Markets in NY and Senior Director, Clinical Operations at a publicly traded Biotech Company. He has 15 years of experience advancing clinical diagnostics and drug discovery & development efforts.

Danny JJ Wang, PhD, MSCE

Co-Founder & Chief Science Officer

Wang is a world leading expert in medical imaging with over 20 years of experience. Dr. Wang also maintains longstanding R&D collaborations with large OEMs including Philips, Siemens, Samsung and Neusoft.

John Detre, MD

Chief Medical Advisor

Director at Center for Functional NeuroImaging. Professor of Neurology & Radiology at University of Pennsylvania

Brian Walsh, MS, MBA

Chief Commercial Advisor

Chief Commercial Advisor
& National Institute of Health Advisor

Hee Kwon Song, PhD

Chief Scientist

Associate Professor of Radiologic Science at University of Pennsylvania

Michael McNitt-Gray, PhD

Chief Science Advisor

Member of Science Advisory Board
Professor of Radiology; Director of Physics & Biology in Medicine Graduate Program; UCLA David Geffen School of Medicine

Thomas Martin, PhD

R&D Scientist, Physics

Medical Physicist

Samantha Ma, MS

R&D Scientist, Artificial Intelligence

Ph.D. Candidate in Biomedical Engineering at University of Southern California

Xin J. Qiao, MD, MS

General Manager & Chief Compliance Officer

Jeffry Alger, PHD

Senior Scientist

Fabien Scalzo, PhD

Senior AI Scientist

Joy Peng, MS

Senior Software Engineer

SIGNIFICANT INNOVATION IN CANCER CARE

Our Partners

Contact Us.

    Your Name (required)

    Your Email (required)

    Subject

    Your Message

    Give us a Call

    215.681.7332